Figure 3 | Scientific Reports

Figure 3

From: A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer

Figure 3

(a) CT-scan of abdomen in patient 102 before baseline (left panel), at baseline (middle panel) and first evaluation at week 8 (right panel). This patient fulfilled the criterion for hyperprogressive disease. (b) CT-scan of abdomen in patient 109 before baseline (left panel), at baseline (middle panel) and first evaluation at wee 8 (right panel). This patient fulfilled the criterion for hyperprogressive disease.

Back to article page